Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JTE-013 is an effective and specific antagonist of S1P2. JTE-013 suppresses the specific binding of radiolabeled S1P to human and rat S1P2 (IC50s: 17 nM and 22 nM, respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 70.00 | |
10 mg | In stock | $ 101.00 | |
25 mg | In stock | $ 224.00 | |
50 mg | In stock | $ 336.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 79.00 |
Description | JTE-013 is an effective and specific antagonist of S1P2. JTE-013 suppresses the specific binding of radiolabeled S1P to human and rat S1P2 (IC50s: 17 nM and 22 nM, respectively). |
Targets&IC50 | S1P2 (rat):22 nM, S1P2 (human):17 nM |
In vitro | JTE-013 is a S1P2 antagonist. JTE-013 (50-200 μM;?1-3 days) decreased cell viability.?JTE-013 shows 4.2% inhibition of S1P3 and does not antagonize S1P1 at concentrations up to 10 μM.?JTE-013 (10-1000 nM;?30 mins) reverses S1P-induced Akt inhibition and inhibits S1P-induced ERK activation. |
In vivo | JTE-013 (gavage;?30 mg/kg daily for 14 consecutive days) decreases tumor size and tumor weight.?the modification of JTE-013 to produce the AB1 compound improved potency, intravenous pharmacokinetics, cellular activity, and antitumor activity in NB and may have enhanced clinical and experimental applicability. |
Molecular Weight | 408.29 |
Formula | C17H19Cl2N7O |
CAS No. | 383150-41-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (244.92 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JTE-013 383150-41-2 Apoptosis GPCR/G Protein S1P Receptor LPL Receptor Inhibitor Lysophospholipid Receptor JTE013 inhibit JTE 013 inhibitor